ASPIC

Interview with Craig Thompson, MD, president and CEO of Memorial Sloan Kettering Cancer Center. From the series «Conversations with Giants in Medicina», at «The Journal of Clinical Investigation».

Interview with Craig Thompson, MD, president and CEO of Memorial Sloan Kettering Cancer Center. From the series «Conversations with Giants in Medicina», at «The Journal of Clinical Investigation».

The Department of Radiotherapy of Hospital de Santa Maria has already published in Brachytherapy, the journal of American Society of Brachytherapy, the results of 17 cases of eyelid carcinomas treated with high-dose-rate interstitial brachytherapy. It is the publication with the largest number of basal cell carcinomas undergoing this type of treatment and the second largest in terms of total number of lesions, including basal and squamous cell carcinomas. With a median followup of 40 months, the local control rate was 94.1%, similar to that achieved with other treatments, including surgery.

O Serviço de Radioterapia do Hospital de Santa Maria publicou recentemente, na revista norte-americana Brachytherapy, o resultado de 17 casos de carcinomas da pálpebra tratados com braquiterapia intersticial de alta taxa de dose. Trata-se da publicação com maior número de basaliomas submetidos a este tipo de tratamento e a segunda maior em termos de número total de lesões, incluindo basaliomas e carcinomas pavimento-celulares. Com um followup mediano de 40 meses, a taxa de controlo local foi de 94,1%, semelhante à alcançada com outros tratamentos, incluindo a cirurgia.

Hotel NH Collection Sevilla, Sevilla, Spain

21-23 October, 2015

See more informations here: http://aseicacongress.es/

Hotel NH Collection Sevilla, Sevilla, Spain

21-23 October, 2015

See more informations here: http://aseicacongress.es/

Palau de Congressos de Catalunya, Barcelona, Spain

12- 15 November, 2015

See more informations here: http://emuc15.uroweb.org/home

Palau de Congressos de Catalunya, Barcelona, Spain

12- 15 November, 2015

See more informations here: http://emuc15.uroweb.org/home

DCA was proposed as a possible cancer therapy, although it was unknown its possible use as cutaneous melanoma therapy. A team of IPATIMUP researchers published a study in Expert Opinion on Therapeutic Targets, where they evaluated the expression profile of pyruvate dehydrogenase kinase isoforms, the DCA targets, in a series of melanoma samples and nevi, and also established the sensitivity of melanoma cell lines to DCA treatment.

O DCA foi proposto como uma possível terapia para cancro, embora fosse desconhecida a sua possível aplicação em melanoma cutâneo. Uma equipa de investigadores do IPATIMUP publicou um estudo na revista Expert Opinion on Therapeutic Targets, onde avaliou a expressão das isoformas de piruvato desidrogenase quinase, as proteínas alvo do DCA, numa serie de melanoma cutâneos e nevos, e também determinou a sensibilidade de linhas celulares derivadas de melanoma cutâneo ao tratamento com DCA.